The Goals to Improve Living with GPP

As a rare condition, generalized pustular psoriasis (GPP) is often misunderstood, leading to prolonged delays for accurate diagnoses, increased misdiagnoses and ineffective treatment. All of these negatively impact on patients' quality of life including their mental health.

Recognising the pressing need for improvement, Boehringer Ingelheim and the wider GPP community have united and taken proactive measures.

The GPP Forum:

In 2022, the GPP Forum brought together patients, patient organizations, rare disease experts and dermatologists, who jointly crafted a transformative initiative known as the GPP Charter. This action plan was developed with the goal of enhancing the lives of individuals affected by GPP. The creation of the GPP Charter exemplifies the collaborative spirit and dedication of the GPP community. The GPP Forum convened a multistakeholder group once again at the World Congress of Dermatology in July 2023 to progress with the Charter goals and share GPP initiatives that are already delivering on these goals.

The Global Delphi Consensus on Goals of generalized pustular psoriasis Treatment and Management

Further, recognizing the absence of consistent guidelines for diagnosing and providing care for GPP patients, a panel of dermatologists took the initiative to address this issue. They formulated The Global Delphi Consensus on Goals of GPP Treatment and Management. By establishing a standardized definition of GPP, the consensus aims to facilitate improved diagnoses and optimize the management of individuals living with GPP. Additionally, the consensus focuses on identifying triggers, distinguishing GPP as a distinct disease, and establishing treatment goals, all with the intention of enhancing the quality of life for those affected by GPP.